Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better

Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better·The Wall Street Journal
David Wainer
2 min read
0
In this article:

AbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. Notably, when AbbVie announced the $8.7 billion acquisition of Cerevel back in December, the main focus of the deal was the experimental schizophrenia drug Emraclidine, part of a new class of medications that target the muscarinic receptor. Late last year, Bristol Myers Squibb also announced its entry into the field, buying Karuna Therapeutics for $14 billion. The Food and Drug Administration is reviewing Karuna’s drug for the treatment of schizophrenia.

Continue reading
Advertisement

Recommended Stories

  • Tesla Interns Say Offers Are Getting Revoked Weeks Before Their Start Date

    (Bloomberg) -- Elon Musk’s latest cost-cutting victims: summer interns.Most Read from BloombergUS and Saudis Near Defense Pact Meant to Reshape Middle EastJerome Powell Offered Markets a Reprieve. It Vanished in a BlinkTesla Axes Supercharger Team in Blow to Broader EV MarketNYPD Arrests Over 300 Protesters in Crackdown on College CampusesThe Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire EconomyTesla Inc. is rescinding offers just weeks before internships were set to start,

  • Ex-Pioneer CEO Barred From Exxon Board for Megadeal to Close

    Antitrust enforcers are set to allege former Pioneer CEO Scott Sheffield discussed coordinating oil-production levels with other producers and OPEC.

  • ExxonMobil’s $60bn Pioneer acquisition nears FTC approval

    The US Federal Trade Commission's (FTC) nod is expected following an agreement that Pioneer's co-founder and ex-CEO, Scott Sheffield, will not join Exxon's board.

  • Senseonics gets FDA clearance to pair CGM implant with insulin pumps

    Analysts said the designation and planned one-year sensor could help Senseonics’ device appeal to more patients.

  • Amgen investors await weight-loss drug data

    (Reuters) -Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told Reuters in an interview.

  • Rio Tinto Declines Comment on Whether Considering Rival Anglo American Bid

    The chair of Rio Tinto declined to comment on whether the world’s second-largest miner by market value is weighing a bid for Anglo American, the target of a recent $39 billion bid by BHP Group.

  • CVS stock crashes after Aetna Medicare Advantage hit

    CVS echoed rivals in forecasting persistent increases in post-covid medical care.

  • This Texas veterinarian helped crack the mystery of bird flu in cows

    The first calls that Dr. Barb Petersen received in early March were from dairy owners worried about crows, pigeons and other birds dying on their Texas farms. Within days, the Amarillo veterinarian was hearing about sick cows with unusual symptoms: high fevers, reluctance to eat and much less milk. Petersen, who monitors more than 40,000 cattle on a dozen farms in the Texas Panhandle, collected samples from cats and cows and sent them to Dr. Drew Magstadt, a friend from college who now works at the veterinary diagnostic laboratory at Iowa State University.

  • Walmart Shuts Health Centers, Virtual Care as Retailer Launches New Grocery Brand

    Walmart Shuts Health Centers, Virtual Care as Retailer Launches New Grocery Brand

  • Boeing Takes Over GKN Plant to Support F/A-18, F-15 Programs

    The aerospace giant also brought along some 550 workers.